Charles Miller
EyeBiotech Ltd. · Wake Forest University Health Sciences · Edward Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Charles Miller as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:48 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07205887 · A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVOEyeBiotech Ltd. · recruiting · Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO) · study director
- Ph2/Ph3NCT06957080 · A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DMEEyeBiotech Ltd. · active not recruiting · Diabetic Macular Edema (DME) · study director
- Ph2/Ph3NCT06571045 · A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DMEEyeBiotech Ltd. · active not recruiting · Diabetic Macular Edema (DME) · study director
- N/ANCT02777203 · Power Morcellation Systems for Laparoscopic Hysterectomy and MyomectomyWake Forest University Health Sciences · completed · Leiomyoma · principal investigator
- N/ANCT01026805 · Clinical Evaluation of the Interlace Medical Hysteroscopic MorcellatorHologic, Inc. · completed · Abnormal Uterine Bleeding, Infertility · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 13 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:48 UTC. The ranking covers the 200 most relevant of 510 PubMed records, and a shared surname and initials can bring in a namesake. All 510 on PubMed
- 1,865 citationsRCR 95.1
- A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.N Engl J Med · 20121,769 citationsRCR 44.2
- Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.N Engl J Med · 20021,596 citationsRCR 29.4
- 913 citationsRCR 16.4
- Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.Clin Infect Dis · 2004527 citationsRCR 16.4
- CT angiography for safe discharge of patients with possible acute coronary syndromes.N Engl J Med · 2012522 citationsRCR 16.1
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.J Hematol Oncol · 2017366 citationsRCR 12.4
- 326 citationsRCR 43.2
- Dexmedetomidine and the reduction of postoperative delirium after cardiac surgery.Psychosomatics · 2009316 citationsRCR 11.8
- Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.Am J Hematol · 2024241 citationsRCR 32.1